



WOMEN **FIRST CANCER SITE**
CERVIX UTERI

CERVIX UTERI
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

CERVICE UTERINA
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	EAR	EAR
ALL SITES, BUT SKIN AND CERVIX UTERI	870	1.23	999	1.37	129	7.00	117	1.45	311	1.25	219	1.15	223	1.18	1.84	3.02
HEAD AND NECK	23	2.41	24	2.45	1	4.15	0	0.00	12	3.63	7	2.71	4	1.55	0.15	0.16
ORAL CAVITY	11	2.29	12	2.44	1	8.30	0	0.00	5	3.07	3	2.32	3	2.23	0.07	0.08
PHARYNX	5	2.08	5	2.03	0	0.00	0	0.00	2	2.34	3	4.55	0	0.00	0.03	0.03
LARYNX	7	2.99	7	2.92	0	0.00	0	0.00	5	6.08	1	1.59	1	1.61	0.05	0.05
OESOPHAGUS	5	1.63	5	1.59	0	0.00	0	0.00	2	1.91	1	1.24	2	2.33	0.02	0.02
STOMACH	45	1.25	45	1.21	0	0.00	11	2.41	11	0.85	11	1.17	12	1.32	0.10	0.09
COLON RECTUM	139	1.39	146	1.43	7	2.66	15	1.32	45	1.31	38	1.43	41	1.49	0.45	0.49
COLON	88	1.24	93	1.28	5	2.69	9	1.13	29	1.20	28	1.49	22	1.11	0.20	0.23
RECTUM	51	1.76	53	1.78	2	2.58	6	1.78	16	1.58	10	1.29	19	2.45	0.25	0.26
LIVER	15	0.94	15	0.91	0	0.00	1	0.55	3	0.55	7	1.68	4	0.88	-0.01	-0.02
GALLBLADDER	14	1.09	14	1.06	0	0.00	0	0.00	5	1.12	4	1.19	5	1.43	0.01	0.01
PANCREAS	27	1.13	27	1.10	0	0.00	6	2.25	12	1.51	4	0.63	5	0.71	0.03	0.03
LUNG	123	2.93	130	3.02	7	6.79	12	2.66	51	3.63	35	3.10	25	2.06	0.93	0.97
SKIN MELANOMA	19	1.20	20	1.23	1	2.51	1	0.56	10	1.74	4	0.92	4	1.01	0.04	0.04
MESOTHELIOMA	4	2.21	4	2.16	0	0.00	0	0.00	1	1.69	1	2.07	2	3.67	0.03	0.02
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	5	1.60	5	1.56	0	0.00	0	0.00	1	0.89	1	1.19	3	3.73	0.02	0.02
BONE	1	1.16	1	1.13	0	0.00	1	9.27	0	0.00	0	0.00	0	0.00	0.00	0.00
BREAST	182	0.86	205	0.94	23	4.31	23	0.97	71	0.93	48	0.83	40	0.74	-0.35	-0.14
CERVIX UTERI	1	0.08	15	1.15	14	37.30	0	0.00	1	0.20	0	0.00	0	0.00	-0.13	0.02
CORPUS UTERI	9	0.25	73	1.97	64	69.56	5	1.22	0	0.00	1	0.10	3	0.32	-0.31	0.40
OVARY	17	0.69	21	0.84	4	6.19	8	2.80	5	0.57	1	0.15	3	0.49	-0.09	-0.05
KIDNEY AND RENAL PELVIS	19	1.16	22	1.31	3	7.38	5	2.80	2	0.36	5	1.12	7	1.52	0.03	0.06
BLADDER AND URINARY TRACT	69	2.91	72	2.96	3	4.84	10	3.75	33	4.11	5	0.80	21	3.13	0.52	0.53
URINARY BLADDER	69	3.12	72	3.18	3	5.19	10	4.02	33	4.40	5	0.85	21	3.36	0.54	0.55
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	8	0.76	8	0.74	0	0.00	0	0.00	3	0.80	4	1.42	1	0.36	-0.03	-0.03
THYROID	18	0.97	19	1.00	1	2.22	0	0.00	8	1.18	5	0.97	5	1.10	-0.01	0.00
HODGKIN LYMPHOMA	7	3.05	7	2.96	0	0.00	2	6.38	3	3.23	1	1.68	1	2.18	0.05	0.05
NON-HODGKIN LYMPHOMA	29	1.11	32	1.19	3	4.50	5	1.71	5	0.55	10	1.42	9	1.27	0.03	0.06
MYELOMA	11	0.98	11	0.96	0	0.00	2	1.57	3	0.78	3	1.01	3	0.97	0.00	-0.01
LEUKAEMIAS	20	1.25	20	1.21	0	0.00	3	1.58	8	1.42	4	0.94	5	1.18	0.05	0.04
LYMPHOID LEUKAEMIAS	7	1.00	7	0.98	0	0.00	2	2.41	2	0.81	1	0.54	2	1.09	0.00	0.00
MYELOID LEUKAEMIAS	12	1.53	12	1.49	0	0.00	1	1.10	6	2.18	2	0.96	3	1.43	0.05	0.04
OTHER LEUKAEMIAS	1	0.83	1	0.80	0	0.00	0	0.00	0	0.00	1	3.20	0	0.00	0.00	0.00
OTHER AND ILL DEFINED SITES	61	1.35	73	1.57	12	9.67	7	1.32	17	1.09	19	1.60	18	1.44	0.18	0.29

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio